In this scenario, since the pleiotropic actions of GLP-1 RAs involve tissues and processes that are hormonally regulated, it is of great interest to ask whether a sexual dimorphism may characterize the response to these agents in the treatment of obesity and/or T2D. The gene discussed is GCG; the disease is type 2 diabetes mellitus.